Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36811   clinical trials with a EudraCT protocol, of which   6078   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-002950-38
    Sponsor's Protocol Code Number:3475-051-00
    National Competent Authority:Germany - PEI
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2015-10-30
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - PEI
    A.2EudraCT number2014-002950-38
    A.3Full title of the trial
    A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphoma
    A.3.2Name or abbreviated title of the trial where available
    A Phase I/II trial of MK-3475 (pembrolizumab) in children’s solid tumors and lymphoma
    A.4.1Sponsor's protocol code number3475-051-00
    A.5.4Other Identifiers
    Name:051Number:051
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/059/2014
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMerck Sharp & Dohme Corp., a subsidiary of Merck
    B.5.2Functional name of contact pointGlobal Clinical Trials Operations
    B.5.3 Address:
    B.5.3.1Street AddressOne Merck Drive, PO Box 100
    B.5.3.2Town/ cityWhitehouse Station, NJ
    B.5.3.3Post code08889-0100
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1267305 5994
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Keytruda
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp & Dohme Limited
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePembrolizumab
    D.3.2Product code MK-3475 (SCH 900475)
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPEMBROLIZUMAB
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codeMK-3475
    D.3.9.3Other descriptive nameAnti-PD-1 monoclonal antibody
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Treatment of advanced melanoma or advanced, relapsed or refractory PD-L1 positive malignant solid tumor or lymphoma in children from 6 months to less than 18 years old.
    E.1.1.1Medical condition in easily understood language
    Advanced childhood cancers including solid tumors, melanoma or lymphoma
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10065147
    E.1.2Term Malignant solid tumor
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    For Advanced Melanoma, Advanced, Relapsed or Refractory Pd-L1 Positive Malignant Solid Tumor or Other Lymphoma, MSI-H Solid Tumor
    Part I:
    -To define the rate of dose-limiting toxicities (DLTs) at the maximum tolerated dose (MTD) or maximum administered dose (MAD) of pembrolizumab when administered as monotherapy to children from 6 months to < 18 years of age pooled across all indications
    Part I and II:
    -To determine the safety and tolerability of pembrolizumab based on AEs, and clinical and laboratory measures in children from 6 months to <18 years of age pooled across cohorts
    For the Relapsed Refractory Classical Hodfkin Lymphoma Cohort
    Part II:
    -To determine the safety and tolerability of pembrolizumab based on AEs and clinical and laboratory measures in children with rrcHL.
    -To evaluate anti-tumor activity of pembrolizumab in the rrcHL Cohort based on the ORR according to the IWG response criteria.

    For a full list of objectives, please refer to the protocol.
    E.2.2Secondary objectives of the trial
    For Advanced Melanoma, Advanced, Relapsed or Refractory Pd-L1 Positive Malignant Solid Tumor or Other Lymphoma, MSI-H Solid Tumor
    Part I:
    -To characterize the PK and pharmacodynamics of pembrolizumab administered as monotherapy to children from 6 mo to < 18 years of age pooled across cohorts/indications.
    Part I and II:
    -To evaluate clinical activity of pembrolizumab within each tumor type i in children form 6 mo of age
    -To assess the change in vaccinated antibody concentrations, and memory B- and T-cell counts
    -To evaluate the relationship between baseline tumor PD-L1 expression and clinical efficacy outcomes.
    For Relapsed Refractory Classical Hodgkin Lymphoma
    Part I and II:
    -To evaluate anti-tumor activity of pembrolizumab in the rrcHL Cohort according to the IWG response criteria
    -To assess the change in vaccinated antibody concentrations, and memory B- and T-cell counts

    For a full list of objectives, please refer to the protocol
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Merck will conduct Future Biomedical Research on DNA (blood) specimens collected during this clinical trial. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose of the correct drug at the correct time.
    E.3Principal inclusion criteria
    1. Be willing and able to provide (and/or their parents or legal guardians) written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
    2. Be between 6 months and less than 18 years of age on the day the prescreen informed consent/assent is signed. Patients who do not require prescreening, must meet the age requirement on the day the main informed consent is signed.
    3. Have histologically or cytologically-documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the patient and treating physician. There is no limit to the number of prior treatment regimens.
    4. Be able to provide tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated (tumors progressing in a prior site of radiation are allowed for characterization, other exceptions may be considered after Sponsor consultation). Samples that require decalcification are not allowed.
    5. Have either advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma as determined by IHC in archival formal fixed paraffin embedded tumor (FFPET) or newly obtained biopsy. For this trial, tumor specimens with positive stroma or at least 1% of cells expressing PD-L1 by IHC will be defined as PD-L1 positive. (Subjects with PD-L1 negative tumors may be enolled in Part II of the trial in selet tumor types where preliminary response is observed)
    6. Have measurable disease based on RECIST 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Subjects with neuroblastoma who do not have measurable disease per RECIST 1.1 but have MIBG-positive evaluable disease may be enrolled.
    7. Have a performance status as defined below:
    • Lansky Play Scale ≥50 for children up to and including 16 years of age;
    • Karnofsky score ≥50 for children > 16 years of age
    •Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
    8. Demonstrate adequate organ function
    9.Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.
    10. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.
    11. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
    12. Six of the 12 subjects in a given dose finding/dose confirmation cohort (i.e. Part I) must weigh ≥16 kg (a minimum of 6 subjects at any given dose are needed for the IL--2 assay, and subjects must weigh ≥16 kg in order to provide a specimen for IL-2 analysis).

    Subject Inclusion Criteria Relapsed or Refractory Classical Hodgkin Lymphoma Cohort

    13. Be willing and able to provide (and/or their parents or legal guardians) written informed consent/assent for the trial. The subject may also provide consent/assent for Future Biomedical Research.
    However, the subject may participate in the main trial without participating in Future Biomedical Research.
    14. Be between 3 years and less than 18 years of age on the day the prescreen
    informed consent is signed. Patients who do not require pre-screening, must meet
    the age requirement on the day the main informed consent is signed.
    15. Have relapsed* or refractory† cHL and are either:
    - Refractory to front-line therapy;
    - High-risk and relapsed from front-line therapy; or
    - Relapsed or refractory to second-line therapy
    *Relapsed: disease progression after most recent therapy
    †Refractory: failure to achieve CR or PR
    16. Be able to provide lymph node biopsy tissue from an archival sample or newly obtained biopsy of a tumor lesion not previously irradiated
    17. Have a performance status as defined in the protocol.
    E.4Principal exclusion criteria
    1. Is currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation/randomization.
    2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the date of allocation/randomization. The use of physiologic doses of corticosteroids (up to 5 mg/m2/day prednisone equivalent)
    may be approved after consultation with the Sponsor.
    3. Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤Grade 1 or at baseline) from adverse events due to
    a previously administered agent.
    4. Has received prior radiotherapy within 2 weeks of start of trial treatment. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation
    pneumonitis. A 1-week washout is permitted for palliative radiation (≤2
    weeks of radiotherapy) to non-CNS disease.
    5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of theskin or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially
    curative therapy are not excluded.
    6. Has known active central nervous system (CNS) metastases and/or
    carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable (Of note, subjects with tumors involving the brain stem are excluded from the study.
    7. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
    8. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement
    therapy for adrenal or pituitary insufficiency, etc.) is not considered a
    form of systemic treatment.
    9. Has a history of (non-infectious) pneumonitis that required steroids or
    current pneumonitis.
    10. Has an active infection requiring systemic therapy.
    11. Has a history or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion
    of the treating investigator.
    12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
    13. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the prescreening or screening visit through 120 days after the last dose of trial treatment.
    14. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)."Subjects with
    melanoma who previously received treatment with ipilimumab are not
    excluded.
    15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV
    1/2 antibodies). No HIV testing is required unless mandated by local health authority.
    16. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). No testing for Hepatitis B and Hepatitis C is requiredunless mandated by local health authority.
    17. Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
    18. Has received a live vaccine within 30 days of planned start of trial drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid
    vaccine. Seasonal influenza vaccines for injection are generally killedvirus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed
    19. Has undergone solid organ transplant at any time, or prior allogeneic
    hematopoietic stem cell transplantation within the last 5 years. (Subjects who have had a nallogeneic hematopoietic transplant greater than 5 years ago are eligible as long as there are no symptoms of GVHD.)
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is objective response rate, defined as the proportion of subjects in the analysis population who have complete response (CR) or partial response (PR) using RECIST 1.1 at any time during the study using RECIST 1.1 for solid tumors and other lymphoma. Response for the primary analysis will be determined by the investigator assessment, and a confirmation assessment is required per RECIST 1.1.

    For the RRCHL Cohort, the primary efficacy endpoint is ORR, defined as the proportion of subjects in the analysis population who have a CR or PR at any time during the study using IWG. Response for the primary analysis for the rrcHL Cohort will be determined by the blinded independent central radiology assessment.

    The primary safety endpoints are AEs graded using CTCAE (Version 4.0) criteria. Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab, including serious adverse events (SAEs).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Safety Endpoints: Dose limiting toxicities will be evaluated in the first cycle of treatment (Q3W dosing) or the first two cycles of treatment (Q2W dosing). Safety endpoints will be evaluated for all treated subjects from initiation of treatment through the protocol defined safety follow-up period of 90 days for SAEs (unless a given subject initiates new anti-cancer therapy, in which case the follow-up period for that subject is 30 days)
    Efficacy Endpoints: Efficacy will be evaluated every 8 weeks after initiation of trial treatment until disease progression.
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints include: (1) duration of response, defined as time from first RECIST 1.1 response to documented PD, death due to any cause, or start of new anti-cancer therapy, whichever occurs first, in subjects who achieve a PR or better; (2) progression-free survival (PFS), defined as the time from the first dosing date to the first documented disease progression according to RECIST 1.1 or death due to any cause, or start of new anti-cancer therapy, whichever occurs first; (3) disease control rate, defined as the proportion of subjects with best overall response of complete responses (CR), partial responses (PR), or stable disease (SD), and (4) overall survival (OS).
    Additional supportive analyses of objective overall response rate, duration of response, and PFS will be conducted using a modified RECIST 1.1 criteria (irRECIST), in which a confirmation assessment of disease progression must be obtained at least 4 weeks after the initial disease assessment indicating progressive disease.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Efficacy will be evaluated every 8 weeks after initiation of trial treatment until disease progression.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Dose Finding with Confirmation in Phase I
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial6
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA6
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    Chile
    France
    Germany
    Israel
    Italy
    Korea, Republic of
    Mexico
    New Zealand
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study may be designated as the time point when all subjects have discontinued the study or are a minimum of 6 months post initial study medication administration. If there remains at least 1 subject still on treatment for at least 6 months, the subject may enter additional treatment cycles. At this point a database lock of the trial may occur to allow the analysis. Any remaining subjects may continue to receive medication and be seen by the investigator per usual standard of care.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 311
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 10
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 130
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 171
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Children between the ages of 6 months and 18 years who may require consent to be given by legally appropriate representative
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 72
    F.4.2.2In the whole clinical trial 311
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-01-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-02-10
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA